<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649529</url>
  </required_header>
  <id_info>
    <org_study_id>T2018-7</org_study_id>
    <nct_id>NCT03649529</nct_id>
  </id_info>
  <brief_title>Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy</brief_title>
  <official_title>Adoptive Immunotherapy for HLA_A2 Genotype gp100 Positive Malignant Melanoma With GPA-TriMAR-T Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timmune Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Affiliated Hospital of Hainan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hainan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Timmune Biotech Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant melanoma have been reported to be characterized with high gp100 expression.
      Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to
      generate the GPA-TriMAR-T cells. When infused back to the patient, the GPA-TriMAR-T cells
      will recognize and kill target cells that express gp100(209-217) peptides in the form MHC-I
      complex, thus eliminating malignant melanoma from the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GPA-TriMAR is a modified chimeric antigen receptor (CAR) that consist of three subunit in
      it's outer membrane domain. The outer membrane domain linked to the inner membrane 4-1BB/CD3ζ
      domain through the transmembrane domain, thus compose the complete chimeric antigen receptor.
      Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to
      generate the GPA-TriMAR-T cells. When infused back to the patient, the modified GPA-TriMAR-T
      cells will recognize and kill malignant melanoma cells in the body, and in the meanwhile the
      other two subunits function to stimulate the innate immune system and enhance GPA-TriMAR-T
      cells tumor Infiltration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells,and then infused back into the patient.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate[CR] （Complete response rate per the revised International Working Group (IWG) Response Criteria）</measure>
    <time_frame>24 months</time_frame>
    <description>Complete response rate per the revised International Working Group (IWG) Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）</measure>
    <time_frame>24 months</time_frame>
    <description>Partial response rate per the revised International Working Group (IWG) Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response （The time from response to relapse or progression）</measure>
    <time_frame>24 months</time_frame>
    <description>The time from response to relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival （The time from the first day of treatment to the date on which disease progresses.）</measure>
    <time_frame>24 months</time_frame>
    <description>The time from the first day of treatment to the date on which disease progresses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival （The number of patient alive, with or without signs of cancer）</measure>
    <time_frame>24 months</time_frame>
    <description>The number of patient alive, with or without signs of cancer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>GPA-TriMAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GPA-TriMAR-T</intervention_name>
    <description>Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.</description>
    <arm_group_label>GPA-TriMAR-T</arm_group_label>
    <other_name>TCR-mimic-CAR-T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All subjects must personally sign and date the consent form before initiating any
             study specific procedures or activities;

          2. All subjects must be able to comply with all the scheduled procedures in the study;

          3. HLA_A2 genotype and gp100 positive malignant melanoma： Ⅳ stage or relapsed after
             surgery or chemotherapy or no available standard therapy;

          4. At least one measurable lesion per RECIST V1.1;

          5. Aged 18 to 69 years;

          6. Expected survival ≥12 weeks; Eastern cooperative oncology group (ECOG) performance
             status of≤2;

          7. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped
             for more than 4 weeks;

          8. All other treatment induced adverse events must have been resolved to ≤grade 1;

          9. Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB&gt;70g/L,
             Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN,
             Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);

        Exclusion Criteria:

          1. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
             requiring iv antimicrobials for management. (Simple UTI and uncomplicated bacterial
             pharyngitis are permitted if responding to active treatment);

          2. Patients with symptomatic central nervous system metastasis, intracranial metastasis,
             and cancer cells found in cerebrospinal fluid are not recommended to participate in
             this study. Symptom free or post-treatment stable disease or disappearance of lesions
             should not be excluded. The specific selection is ultimately determined by the
             investigator;

          3. Lactating women or women of childbearing age who plan to conceive during the time
             period;

          4. Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV
             positive);

          5. Known history of infection with HIV;

          6. Subjects need systematic usage of corticosteroid;

          7. Subjects need systematic usage of immunosuppressive drug;

          8. Planed operation, history of other related disease, or any other related laboratory
             tests restrict patients for the study;

          9. Other reasons the investigator consider the patient may not be suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haifeng Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Hainan Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haifeng Lin</last_name>
    <phone>+86 13322060949</phone>
    <email>13322060949@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bin Gao</last_name>
    <phone>+86 13910899150</phone>
    <email>bin.gaoa@timmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hainan Cancer Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuyang Tian</last_name>
      <phone>+86 18686853849</phone>
      <email>tianyuyang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hainan Medical University</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haifeng Lin</last_name>
      <phone>+86 13322060949</phone>
      <email>13322060949@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yasong Wu</last_name>
      <phone>+86 18020091931</phone>
      <email>yasong.wu@timmune.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, Han H, He W, Wang W, Zhao Y, Liu C, Sun M, Gao B. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep. 2014 Jan 6;4:3571. doi: 10.1038/srep03571.</citation>
    <PMID>24389689</PMID>
  </reference>
  <reference>
    <citation>Zhang G, Liu R, Zhu X, Wang L, Ma J, Han H, Wang X, Zhang G, He W, Wang W, Liu C, Li S, Sun M, Gao B. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol. 2013 Nov-Dec;91(10):615-24. doi: 10.1038/icb.2013.45. Epub 2013 Oct 8.</citation>
    <PMID>24100387</PMID>
  </reference>
  <reference>
    <citation>Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Review.</citation>
    <PMID>28925994</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HLA-A2</keyword>
  <keyword>gp100</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

